相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition
Marco H. Hofmann et al.
CANCER DISCOVERY (2021)
Genomic landscape of lung adenocarcinoma in East Asians
Jianbin Chen et al.
NATURE GENETICS (2020)
Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines
Dorna Varshavi et al.
METABOLOMICS (2020)
An In Vivo Kras Allelic Series Reveals Distinct Phenotypes of Common Oncogenic Variants
Maria Paz Zafra et al.
CANCER DISCOVERY (2020)
Diagnostic Strategies toward Clinical Implementation of Liquid Biopsy RAS/BRAF Circulating Tumor DNA Analyses in Patients with Metastatic Colorectal Cancer
Iris van 't Erve et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2020)
KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
David S. Hong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
High Glucose Triggers Nucleotide Imbalance through O-GlcNAcylation of Key Enzymes and Induces KRAS Mutation in Pancreatic Cells
Chun-Mei Hu et al.
CELL METABOLISM (2019)
Tissue-Specific Oncogenic Activity of KRASA146T
Emily J. Poulin et al.
CANCER DISCOVERY (2019)
G12V and G12C mutations in the gene KRAS are associated with a poorer prognosis in primary colorectal cancer
Tamuro Hayama et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2019)
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Jude Canon et al.
NATURE (2019)
Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients
Ilya G. Serebriiskii et al.
NATURE COMMUNICATIONS (2019)
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patients
Steven M. Bray et al.
SCIENTIFIC REPORTS (2019)
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Carmen Munoz-Maldonado et al.
FRONTIERS IN ONCOLOGY (2019)
Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients
Martina Rebersek et al.
RADIOLOGY AND ONCOLOGY (2019)
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Rona Yaeger et al.
CANCER CELL (2018)
RAS nucleotide cycling underlies the SHP2 phosphatase dependence of mutant BRAF-, NF1-and RAS-driven cancers
Robert J. Nichols et al.
NATURE CELL BIOLOGY (2018)
A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
Alison M. Schram et al.
BRITISH JOURNAL OF CANCER (2018)
Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis
Naiara Santana-Codina et al.
NATURE COMMUNICATIONS (2018)
Oncogenic Ras Isoforms Signaling Specificity at the Membrane
Ruth Nussinov et al.
CANCER RESEARCH (2018)
How close are we to standardised extended RAS gene mutation testing? The UK NEQAS evaluation
Susan D. Richman et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Dual PI3K/mTOR Inhibition in Colorectal Cancers with APC and PIK3CA Mutations
Tyler M. Foley et al.
MOLECULAR CANCER RESEARCH (2017)
Tracking the Evolution of Non-Small-Cell Lung Cancer
M. Jamal-Hanjani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
RAS Proteins and Their Regulators in Human Disease
Dhirendra K. Simanshu et al.
CELL (2017)
Molecular Biomarkers for the Evaluation of Colorectal Cancer Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology
Antonia R. Sepulveda et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2017)
Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer
Robert P. Jones et al.
BRITISH JOURNAL OF CANCER (2017)
Genomic analyses identify molecular subtypes of pancreatic cancer
Peter Bailey et al.
NATURE (2016)
Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Joshua D. Campbell et al.
NATURE GENETICS (2016)
Treatment strategies in colorectal cancer patients with initially unresectable liver-only metastases, a study protocol of the randomised phase 3 CAIRO5 study of the Dutch Colorectal Cancer Group (DCCG)
Joost Huiskens et al.
BMC CANCER (2015)
Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer
J. Randolph Hecht et al.
CANCER TREATMENT REVIEWS (2015)
Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials
M. Peeters et al.
EUROPEAN JOURNAL OF CANCER (2015)
Prognostic role of KRAS, NRAS, BRAF and PIK3CA mutations in advanced colorectal cancer
Luisa Foltran et al.
FUTURE ONCOLOGY (2015)
Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
Agnieszka K. Witkiewicz et al.
NATURE COMMUNICATIONS (2015)
Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis
Georgios Antonios Margonis et al.
JAMA SURGERY (2015)
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis
Christina Therkildsen et al.
ACTA ONCOLOGICA (2014)
Analyses of clinicopathological, molecular, and prognostic associations of KRAS codon 61 and codon 146 mutations in colorectal cancer: cohort study and literature review
Yu Imamura et al.
MOLECULAR CANCER (2014)
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer
V. Eklof et al.
BRITISH JOURNAL OF CANCER (2013)
PIK3CA Mutation H1047R Is Associated with Response to PI3K/AKT/mTOR Signaling Pathway Inhibitors in Early-Phase Clinical Trials
Filip Janku et al.
CANCER RESEARCH (2013)
Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer
Areumnuri Kim et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway
Jaekyoung Son et al.
NATURE (2013)
Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Jean-Yves Douillard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis
Claire L. Vale et al.
CANCER TREATMENT REVIEWS (2012)
Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura et al.
CLINICAL CANCER RESEARCH (2012)
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi et al.
CLINICAL CANCER RESEARCH (2012)
Association of KRAS G13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab
Sabine Tejpar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Ethan Cerami et al.
CANCER DISCOVERY (2012)
Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer
Manickam Janakiraman et al.
CANCER RESEARCH (2010)
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Wendy De Roock et al.
LANCET ONCOLOGY (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
Jeffrey A. Engelman et al.
NATURE MEDICINE (2008)
The consensus coding sequences of human breast and colorectal cancers
Tobias Sjoeblom et al.
SCIENCE (2006)
Recurrent KRAS Codon 146 mutations in human colorectal cancer
Sarah Edkins et al.
CANCER BIOLOGY & THERAPY (2006)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
分享论文
